Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited announced the issuance of 843,574 fully paid ordinary shares to an executive as part of their remuneration under the Executive Share Plan for the quarter ended September 30, 2025. This move reflects the company’s strategic approach to executive compensation, potentially impacting its financial operations and signaling a commitment to aligning executive interests with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices. The company’s primary products include devices for measuring, monitoring, and managing fluid status and body composition, with a market focus on healthcare providers and patients requiring precise body fluid assessments.
Average Trading Volume: 1,825,698
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.